2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

Evidence-based health promotion and disease prevention are foundational to the AGPCNP scope of practice. Health screening involves the systematic identification of asymptomatic disease at a preclinical stage where clinical intervention alters the natural history of the illness. Clinical preventive services must adhere to the rigor of the U.S. Preventive Services Task Force (USPSTF), while adult immunizations must strictly align with the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC).

---

1. The USPSTF Grading System & Methodological Framework

The USPSTF assigns evidence grades based on the certainty and magnitude of net clinical benefit (benefits minus harms):

+---------------------------------------------------------------------------------------------------+
|                             USPSTF RECOMMENDATION GRADING SYSTEM                                  |
|                                                                                                   |
|   GRADE       CLINICAL DEFINITION                                 PRACTICE DIRECTIVE              |
|   =====       =================================================   =============================   |
|     A         High certainty that net benefit is substantial.     OFFER / PROVIDE ROUTINELY       |
|     B         High certainty of moderate net benefit, or          OFFER / PROVIDE ROUTINELY       |
|               moderate certainty of moderate-to-substantial net.                                  |
|     C         Moderate certainty that net benefit is small;       SELECTIVE OFFERING BASED ON     |
|               clinical benefit depends on individual context.     SHARED DECISION-MAKING          |
|     D         Moderate/high certainty that service has NO net     DISCOURAGE / DO NOT PROVIDE     |
|               benefit, or harms outweigh the benefits.            (RECOMMEND AGAINST)             |
|     I         Current evidence is INSUFFICIENT to assess the      CLINICAL JUDGMENT; EXPLAIN      |
|               balance of benefits and harms.                      UNCERTAINTY TO PATIENT          |
+---------------------------------------------------------------------------------------------------+

The "10-Year Life Expectancy Rule" in Screening Cessation

Almost all cancer screening trials demonstrate that a minimum of 10 to 15 years of life expectancy is required to realize a statistically significant reduction in disease-specific mortality. Performing invasive screening in patients with a life expectancy $<10\text{ years}$ exposes the older adult to immediate procedural harms (biopsy bleeding, colonic perforation, false-positive anxiety, overtreatment) with zero probability of lifetime survival benefit.

---

2. Evidence-Based Cancer Screening Master Guidelines (USPSTF)

+---------------------------------------------------------------------------------------------------+
|                         USPSTF CANCER SCREENING RECOMMENDATIONS MASTER MATRIX                     |
|                                                                                                   |
|   CANCER TYPE       POPULATION & AGE RANGE        SCREENING MODALITY & INTERVAL           GRADE   |
|   ===========       ======================        =============================           =====   |
|   Colorectal        Adults aged 45 to 75          Colonoscopy q10y, OR                    Grade A |
|                                                   Annual high-sensitivity FIT/gFOBT, OR           |
|                                                   sDNA-FIT (Cologuard) q1-3y, OR                  |
|                                                   CT Colonography q5y, OR                         |
|                                                   Flexible Sigmoidoscopy q5y                      |
|                     ---------------------------------------------------------------------------   |
|                     Adults aged 76 to 85          Selective individual decision (prior    Grade C |
|                                                   screening, health status, life exp >10y)        |
|                     ---------------------------------------------------------------------------   |
|                     Adults aged >= 86             DISCONTINUE SCREENING                   Grade D |
|   ---------------------------------------------------------------------------------------------   |
|   Breast            Females aged 40 to 74         Biennial (every 2 years) screening      Grade B |
|                                                   digital mammography                             |
|                     ---------------------------------------------------------------------------   |
|                     Females aged >= 75            Evidence Insufficient                   Grade I |
|   ---------------------------------------------------------------------------------------------   |
|   Cervical          Females aged 21 to 29         Cervical cytology (Pap) alone q3y       Grade A |
|                     ---------------------------------------------------------------------------   |
|                     Females aged 30 to 65         Cytology alone q3y, OR                  Grade A |
|                                                   hrHPV testing alone q5y, OR                     |
|                                                   Cytology + hrHPV Cotesting q5y                  |
|                     ---------------------------------------------------------------------------   |
|                     Females aged > 65 with        DISCONTINUE SCREENING                   Grade D |
|                     adequate prior screening                                                      |
|                     ---------------------------------------------------------------------------   |
|                     Total Hysterectomy with       DISCONTINUE SCREENING                   Grade D |
|                     removal of cervix (benign)                                                    |
|   ---------------------------------------------------------------------------------------------   |
|   Lung              Adults aged 50 to 80 with     Annual Low-Dose Computed Tomography     Grade B |
|                     >=20 pack-year smoking hist,  (LDCT). Discontinue once quit >=15 yrs          |
|                     current smoker or quit <15y   or develops life-limiting illness.              |
|   ---------------------------------------------------------------------------------------------   |
|   Prostate          Males aged 55 to 69           Individualized shared decision-making   Grade C |
|                                                   regarding periodic PSA testing                  |
|                     ---------------------------------------------------------------------------   |
|                     Males aged >= 70              DISCONTINUE / DO NOT SCREEN             Grade D |
+---------------------------------------------------------------------------------------------------+

In-Depth Cancer Screening Protocols

A. Colorectal Cancer Screening (CRC)

• Target Population: Universal screening initiates at age 45 and continues through age 75 (Grade A).
• Screening Options:
  1. High-sensitivity Fecal Immunochemical Test (FIT) or Guaiac-based FOBT (gFOBT): Annually.
  2. Stool DNA-FIT (sDNA-FIT / Cologuard): Every 1 to 3 years. (Note: Any positive stool-based test mandates a diagnostic colonoscopy).
  3. Optical Colonoscopy: Every 10 years (gold standard; visualizes entire colon and allows therapeutic polypectomy).
  4. Computed Tomography Colonography (Virtual Colonoscopy): Every 5 years.
  5. Flexible Sigmoidoscopy: Every 5 years (or every 10 years if combined with annual FIT).
• Older Adults (Ages 76–85): Grade C. Do not screen routinely; offer only to healthy individuals who have never been screened and have substantial life expectancy.
• Discontinuation: Age $>85$ years (Grade D).

B. Breast Cancer Screening

• Target Population: Biennial (every 2 years) screening mammography for women aged 40 to 74 years (Grade B).
• Discontinuation: Evidence is insufficient (Grade I) for screening mammography in women aged $\ge 75$ years.
• Ineffective Modalities: Clinical Breast Examination (CBE) alone is Grade I (insufficient evidence); routine breast self-examination (BSE) is discouraged as it increases benign breast biopsies without reducing mortality.

C. Cervical Cancer Screening

• Ages 21–29: Cervical cytology (Pap smear) alone every 3 years (Grade A). Do NOT perform HPV testing in women $<30$ years (high prevalence of transient, self-clearing HPV infections leads to unnecessary colposcopies).
• Ages 30–65: Choice of three acceptable strategies (Grade A):
  1. Cytology alone every 3 years.
  2. High-risk HPV (hrHPV) testing alone every 5 years.
  3. Cytology + hrHPV cotesting every 5 years.
• Screening Cessation (Age >65): Discontinue screening if the patient has adequate prior negative screening (defined as 3 consecutive negative cytology results OR 2 consecutive negative hrHPV/cotesting results within the past 10 years, with the most recent test occurring within the past 5 years) and is not at high risk (Grade D).
• Post-Hysterectomy: Discontinue screening if the cervix was removed for benign disease (e.g., fibroids, prolapse) with no prior history of CIN 2, CIN 3, or cervical cancer (Grade D).

D. Lung Cancer Screening

• Eligibility Criteria (All 3 Must Be Met - Grade B):
  1. Age 50 to 80 years.
  2. $\ge 20$ pack-year cigarette smoking history.
  3. Currently smokes OR has quit within the preceding 15 years.
• Modality: Annual Low-Dose Computed Tomography (LDCT).
• Discontinuation Rules: Stop screening once the individual reaches age 81, OR has been continuously abstinent from smoking for $\ge 15\text{ years}$, OR develops a severe health condition that limits life expectancy or precludes curative pulmonary surgery.

E. Prostate Cancer Screening

• Men Ages 55–69 (Grade C): Clinicians should engage in structured Shared Decision-Making, discussing the modest potential benefit of reducing prostate cancer mortality versus the frequent harms of false-positive results, biopsy complications (infection, bleeding), and treatment-related permanent erectile dysfunction and urinary incontinence.
• Men Age $\ge 70$ (Grade D): Recommend against PSA screening.

---

3. Cardiovascular, Metabolic & Infectious Screening (USPSTF)

+---------------------------------------------------------------------------------------------------+
|                         CARDIOVASCULAR & METABOLIC SCREENING PROTOCOLS                            |
|                                                                                                   |
|   CONDITION         TARGET POPULATION                     MODALITY & FREQUENCY            GRADE   |
|   =========         =================                     ====================            =====   |
|   Abdominal Aortic  Men aged 65 to 75 who have            One-time abdominal ultrasound   Grade B |
|   Aneurysm (AAA)    EVER smoked (>=100 lifetime cigs)                                             |
|                     ---------------------------------------------------------------------------   |
|                     Men aged 65 to 75 who NEVER smoked    Selective individual decision   Grade C |
|                     ---------------------------------------------------------------------------   |
|                     Women who NEVER smoked                DO NOT SCREEN                   Grade D |
|   ---------------------------------------------------------------------------------------------   |
|   Hypertension      Adults aged >= 18                     Office BP measurement. Confirm  Grade A |
|                                                           with out-of-office ABPM/HBPM.   |
|                                                           Annually if >=40 or high risk.  |
|   ---------------------------------------------------------------------------------------------   |
|   Type 2 Diabetes / Asymptomatic adults aged 35 to 70     Fasting plasma glucose, HbA1c,  Grade B |
|   Prediabetes       who are overweight/obese (BMI >=25,   or 2-hr OGTT. Repeat every 3y   |
|                     or >=23 in Asian Americans)           if normal.                      |
|   ---------------------------------------------------------------------------------------------   |
|   Osteoporosis      Women aged >= 65                      Dual-Energy X-ray Absorptiometry Grade B|
|                                                           (DEXA) scan of hip and spine.   |
|                     ---------------------------------------------------------------------------   |
|                     Postmenopausal women <65 with         DEXA scan if FRAX 10-year major Grade B |
|                     increased clinical fracture risk      fracture risk >= 8.4%.          |
|   ---------------------------------------------------------------------------------------------   |
|   Lipid Disorders / Adults aged 40 to 75 with no CVD,     Fasting lipid panel; initiate   Grade B |
|   Statin Primary    >=1 CVD risk factor (HTN, DM, smoking,low-to-moderate intensity statin        |
|   Prevention        dyslipidemia), and ASCVD risk >=10%   (Grade C if ASCVD 7.5% - <10%).         |
+---------------------------------------------------------------------------------------------------+

Infectious Disease & Behavioral Health Screening

• HIV Screening: Universal screening for all individuals aged 15 to 65 years and all pregnant individuals (Grade A).
• Hepatitis C Virus (HCV): One-time universal screening for all adults aged 18 to 79 years with anti-HCV antibody testing followed by confirmatory reflex HCV RNA PCR (Grade B).
• Hepatitis B Virus (HBV): CDC has recommended universal one-time screening of all adults aged $\ge 18$ years since March 2023, using the triple panel - HBsAg, anti-HBc (total) and anti-HBs - drawn at the same visit. Risk-based periodic re-testing is layered on top for people with ongoing exposure (people who inject drugs, MSM, people on hemodialysis, HIV-positive patients, household or sexual contacts of HBsAg-positive people, and incarcerated people). Pregnant patients are screened with HBsAg in every pregnancy, preferably in the first trimester. The older risk-factor-only screening model is a common stale distractor.
• Chlamydia & Gonorrhea: Screen all sexually active women $\le 24$ years, and women $\ge 25$ years at increased risk (new or multiple partners) with urine NAAT (Grade B).
• Major Depressive Disorder: Screen all adults, including older adults and postpartum women, using standardized instruments (PHQ-2, followed by PHQ-9 if positive) (Grade B).
• Unhealthy Alcohol Use: Screen all adults $\ge 18$ using AUDIT-C or single-item screener, providing brief behavioral counseling for positive results (Grade B).

---

4. CDC / ACIP Adult Immunization Schedules

Adult immunization prevents $>50,000$ adult deaths annually in the United States. Vaccination schedules require precision in indications, intervals, and contraindications.

+---------------------------------------------------------------------------------------------------+
|                         ACIP ADULT IMMUNIZATION MASTER SCHEDULE                                   |
|                                                                                                   |
|   VACCINE           INDICATED POPULATION                  DOSING SCHEDULE & ROUTE                 |
|   =======           ====================                  =======================                 |
|   Influenza         All adults >= 6 months annually       1 dose annually in autumn.              |
|                     (Preferential high-dose / adjuvanted  - High-Dose Inactivated (HD-IIV4),      |
|                      formulation for adults >= 65)         Recombinant (RIV4), or Adjuvanted (aIIV4)|
|   ---------------------------------------------------------------------------------------------   |
|   Pneumococcal      All adults >= 50 (age lowered from    OPTION 1: PCV20 alone (1 dose), OR      |
|   (Conjugate /      65 to 50 by ACIP in Oct 2024), and    OPTION 2: PCV21 alone (1 dose), OR      |
|    Polysaccharide)  adults 19-49 with high-risk chronic   OPTION 3: PCV15 (1 dose) followed by    |
|                     conditions or immunocompromise        PPSV23 >= 1 year later (>= 8 wks if     |
|                                                           immunocompromised, CSF leak, cochlear   |
|                                                           implant).                               |
|   ---------------------------------------------------------------------------------------------   |
|   Zoster            All adults >= 50 years (and           2-dose series: Intramuscular (IM)       |
|   (Shingrix - RZV)  immunocompromised adults >= 19)       at 0 and 2 to 6 months.                 |
|   ---------------------------------------------------------------------------------------------   |
|   Tdap / Td         All adults (every pregnancy;          1 dose Tdap (if never received), then   |
|                     wound prophylaxis; decennial booster) Td or Tdap booster every 10 years.      |
|                                                           Give Tdap at 27-36 wks each pregnancy.  |
|   ---------------------------------------------------------------------------------------------   |
|   RSV               All adults >= 75 routinely;           Single dose (Arexvy, Abrysvo or mResvia)|
|   (Respiratory      Adults aged 50 to 74 at INCREASED     IM in late summer / early autumn before |
|    Syncytial Virus) risk (chronic cardiopulmonary, renal, RSV season. Not currently an annual     |
|                     hepatic, hematologic or neurologic    dose - one dose only.                   |
|                     disease, diabetes, severe obesity,                                            |
|                     immunocompromise, frailty, or         (The 50-59 at-risk expansion was voted  |
|                     nursing-home residence)               by ACIP 16 Apr 2025.)                   |
|   ---------------------------------------------------------------------------------------------   |
|   Hepatitis B       All adults aged 19 to 59;             2-dose series (Heplisav-B at 0, 1 mo) or|
|                     Adults >= 60 with risk factors        3-dose series (Engerix-B at 0, 1, 6 mo).|
|   ---------------------------------------------------------------------------------------------   |
|   HPV (9-valent)    All adults through age 26;            2 doses (if started <15y) or            |
|                     Adults 27 to 45 (shared decision)     3 doses at 0, 1-2, 6 months.            |
+---------------------------------------------------------------------------------------------------+

[!IMPORTANT] Three adult-schedule changes that stale prep material still gets wrong:

1. Pneumococcal age is 50, not 65. ACIP voted in October 2024 and CDC endorsed lowering the routine age-based pneumococcal recommendation from 65 to 50 years. A vaccine-naive 55-year-old with no chronic disease is now due.
2. PCV21 (Capvaxive) exists. ACIP recommended PCV21 in June 2024 as a single-dose option for adults for whom pneumococcal vaccination is indicated, alongside PCV20 and the PCV15-then-PPSV23 sequence. A PCV21 recipient needs no PPSV23.
3. RSV starts at 50 for at-risk adults. Routine vaccination is >= 75 years; ACIP added 50-74 years with increased-risk conditions (the 50-59 expansion was voted 16 April 2025 and adopted 25 June 2025). Answer choices still written as "60-74" reflect the superseded 2023-2024 recommendation.

Critical Clinical Vaccine Rules & Pitfalls:

A. Pneumococcal Vaccination Protocols (current ACIP recommendation)

For any vaccine-naive adult aged $\ge 50$ years (or adult 19–49 with diabetes, COPD, asthma, chronic heart/liver/renal disease, cigarette smoking, asplenia, or immunocompromise):

• Simplified Standard Pathway: Administer 1 single dose of PCV20 (Prevnar 20). No subsequent pneumococcal vaccines are needed.
• Alternative Pathway: Administer 1 dose of PCV15 (Vaxnevis), followed $\ge 1\text{ year}$ later by 1 dose of PPSV23 (Pneumovax 23). (Exception: In immunocompromised patients, CSF leaks, or cochlear implants, the interval between PCV15 and PPSV23 is shortened to $\ge 8\text{ weeks}$).
• (Board Trap: PCV20 and PCV15 should NEVER be co-administered; PPSV23 should NEVER be given alone as the initial vaccine if conjugate vaccines are available).

B. Recombinant Zoster Vaccine (Shingrix - RZV)

• Administer 2 doses of RZV (0.5 mL IM) separated by 2 to 6 months to all adults $\ge 50$ years.
• Previous Zoster Episode: Administer regardless of prior clinical shingles history (natural infection does not confer lifelong immunity).
• Previous Zostavax (ZVL) Live Vaccine: Administer RZV to patients who previously received the discontinued live zoster vaccine (wait $\ge 2\text{ months}$ after Zostavax).
• Immunocompromised Adults: Indicated for adults $\ge 19$ years who are or will be immunosuppressed (dosing interval may be shortened to 1–2 months).

C. Respiratory Syncytial Virus (RSV) Vaccine

• Recommended as a single lifetime dose (Arexvy [GSK] or Abrysvo [Pfizer]) for:
  1. All adults aged $\ge 75$ years.
  2. Adults aged 60 to 74 years who are at increased risk for severe RSV disease (chronic heart failure, COPD, asthma, end-stage renal disease, diabetes mellitus, severe obesity, or residing in nursing homes).

D. Live Attenuated Vaccines: Absolute Contraindications

Live attenuated vaccines (e.g., MMR, Varicella, Yellow Fever):

• Strictly Contraindicated in:
  1. Pregnancy (risk of congenital viral infection).
  2. Severe Immunosuppression (solid organ transplant recipients, active chemotherapy, biologic immunosuppressants [TNF-alpha inhibitors], CD4 T-lymphocyte count $<200\text{ cells/}\mu\text{L}$, or high-dose systemic corticosteroid therapy [$\ge 20\text{ mg/day}$ prednisone equivalent for $\ge 14\text{ consecutive days}$]).